17 Jun 08
Cimzia (certolizumab pegol) is the first and so far, only, PEGylated, Fc-Free, anti-tumour necrosis factor (TNF) alpha treatment in development for rheumatoid arthritis. Data presented at the Annual European Rheumatology Congress (EULAR) suggest that, in combination with methotrexate, Cimzia acts fast to significantly suppress disease activity, prevent structural damage to joints, preserve physical function and help patients continue working productively.
Olwen Glynn Owen - Pharmiweb Field reporter
09 Jun 08
Of patients with lung cancer, 80 per cent have non-small cell lung cancer (NSCLC) and of those, 40 per cent are not diagnosed until their disease is advanced and has spread to other organ sites. Current targeted treatment has improved survival but is not suitable for all. Now a new trial, FLEX, shows adding the targeted therapy Erbitux (cetuximab) to chemotherapy increases survival for all types of NSCLC.
Olwen Glynn Owen - PharmiWeb.com Field Reporter
21 May 08
We have an enviable position of being visited by over 150,000 people each month looking for pharmaceutical news and jobs, and we need to satisfy their desire for content.
13 May 08
In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments.
09 May 08
“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
Nini Wei- Visiongain Ltd
11 Apr 08
Which current or future therapies will drive the sleep disorders market from 2008 to 2018?
What is the patient identification rate for each of the therapeutic areas?
What is the present state of the disease awareness?
What R&D opportunities exist for ‘new comers’?
Which key companies are involved in the market?
01 Apr 08
Forget sweat patches, VPLs and spots…a new survey commissioned by Kleenex® has found that it’s blowing your nose in public that causes us the most embarrassment! The survey of hay fever sufferers reveals that most people prefer a quiet sniff over a good nose blow when out and about. However, allergy specialists warn that the more discreet option actually makes symptoms worse.
31 Mar 08
Asthma is a significant health problem. Acording to the National Asthma Campaign, the condition continues to grow, and in the UK an estimated 8 million people are diagnosed as having asthma, with 5 million people receiving treatment. The cost of asthma to the NHS is more than £850 million a year.
25 Mar 08
Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
12 Mar 08
Research led by the University of Warwick has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin. The same research could also open up MRSA to attack by penicillin and help create a library of designer antibiotics to use against a range of other dangerous bacteria.
20 Feb 08
In case you hadn’t noticed, mobile phone manufacturers – and the operators – are desperate to part you from your cash in return for a flash new device. So, to help you decide if you should give in to temptation, we have reviewed three of the latest smartphones that the market has to offer.
PharmiWeb.com - editor
30 Jan 08
-The European Commission has granted a broad label expansion for Avastin in combination with any standard chemotherapy in first and later treatment lines for patients with metastatic colorectal cancer.
-This broad approval mean that virtually all patients currently suffering from colorectal cancer that has spread to other parts of the body will now have access to effective new treatments that have proven survival benefits.
-The approval is based on the results of two large internationa
04 Dec 07
Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication.
Olwen Glynn Owen - Pharmiweb Field Reporter
25 Sep 07
Two things; firstly among all of the great business concepts of the last few
decades the franchise model has always surfaced to the very top. Secondly,
over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
06 Sep 07
Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP).
Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
07 Aug 07
Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago.
Olwen Glynn Owen
25 Jul 07
Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007
second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to
$5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half.
Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7%
for the 2007 second quarter and 8% for the 2007 first half.
20 Jul 07
First medicine shown to extend survival of previously untreated lung cancer patients beyond one year.
02 Jul 07
Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
11 Jun 07
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen
08 Jun 07
Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen
05 Jun 07
In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
04 Jun 07
Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen
23 May 07
In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.